Oral Colonization and Anti-fungal Susceptibility Pattern in Patients with Hematological Malignancy

Overview

Journal Curr Med Mycol

Date 2023 Apr 13

PMID 37051553

Authors

Maryam Talebshoushtari Zadeh

Ensieh Lotfali

Mahsa Fattahi

Sara Abolgasemi

Affiliations

Soon will be listed here.

Abstract

Background And Purpose: Candidiasis is regarded as one of the most important fungal infections and a cause of disease and mortality in patients with hematological malignancy. Accordingly, antifungal prophylaxis is of significant importance in this regard. This study aimed to identify the epidemiology of colonization and evaluate its antifungal susceptibility pattern in patients with hematological malignancy.

Materials And Methods: In this study, the samples were collected from the oral cavity of 100 patients, and colonization was confirmed by fungal culture. strains were also identified by ITS-PCR. antifungal susceptibility tests against fluconazole, amphotericin B, and caspofungin were performed according to CLSI M60.

Results: Demographic characteristics, comorbidities, distribution of species (spp.), and antifungal susceptibility were analyzed in this study. The study participants included 100 patients with a mean age of 15.48%±48.74 years (age range: 17-84 years). Regarding gender distribution, the majority (64%) of the patients were male. In terms of the distribution of underlying hematologic malignancy, 27% of the cases had lymphoma. The most commonly isolated species among patients were complex (49%; n=49), (39%; n=39), and co-colonization of complex and with (10%; n=10). The overall resistance of complex was 5% to fluconazole (n=5) and 2% to amphotericin B (n=2). Furthermore, showed 11% (n=11) resistance to fluconazole and was susceptible to amphotericin B. All spp. isolated from patients who were susceptible to caspofungin.

Conclusion: The high rate of colonization of spp., especially the significant increase in the frequency of in patients with blood malignancies and the gradual increase in resistance to fluconazole, necessitate a change in the use of antifungal drugs for the prevention and experimental treatment of hematological malignancy.

References

Lotfali E, Mardani M, Abolghasemi S, Darvishnia D, Rabiei M, Ghasemi R . Isolation of in oral candidiasis: First report among cancer patients in Iran. Curr Med Mycol. 2021; 6(2):58-62. PMC: 7888514. DOI: 10.18502/CMM.6.2.2695. View

Nivoix Y, Velten M, Letscher-Bru V, Moghaddam A, Natarajan-Ame S, Fohrer C . Factors associated with overall and attributable mortality in invasive aspergillosis. Clin Infect Dis. 2008; 47(9):1176-84. DOI: 10.1086/592255. View

Lee C, Lin C, Ho C, Lin J . Primary Fungal Prophylaxis in Hematological Malignancy: a Network Meta-Analysis of Randomized Controlled Trials. Antimicrob Agents Chemother. 2018; 62(8). PMC: 6105838. DOI: 10.1128/AAC.00355-18. View

Rajendran R, Sherry L, Deshpande A, Johnson E, Hanson M, Williams C . A Prospective Surveillance Study of Candidaemia: Epidemiology, Risk Factors, Antifungal Treatment and Outcome in Hospitalized Patients. Front Microbiol. 2016; 7:915. PMC: 4910670. DOI: 10.3389/fmicb.2016.00915. View

Sakamoto Y, Isono H, Enoki Y, Taguchi K, Miyazaki T, Kunimoto H . Population Pharmacokinetic Analysis and Dosing Optimization of Prophylactic Fluconazole in Japanese Patients with Hematological Malignancy. J Fungi (Basel). 2021; 7(11). PMC: 8618010. DOI: 10.3390/jof7110975. View

Haddadi P, Zareifar S, Badiee P, Alborzi A, Mokhtari M, Zomorodian K . Yeast colonization and drug susceptibility pattern in the pediatric patients with neutropenia. Jundishapur J Microbiol. 2014; 7(9):e11858. PMC: 4255375. DOI: 10.5812/jjm.11858. View

Slavin M, Van Hal S, Sorrell T, Lee A, Marriott D, Daveson K . Invasive infections due to filamentous fungi other than Aspergillus: epidemiology and determinants of mortality. Clin Microbiol Infect. 2015; 21(5):490.e1-10. DOI: 10.1016/j.cmi.2014.12.021. View

Yasu T, Sakurai K, Akazawa M . Invasive Fungal Disease in Patients with Chronic Lymphocytic Leukemia in Japan: A Retrospective Database Study. Curr Oncol. 2022; 29(5):3242-3251. PMC: 9139551. DOI: 10.3390/curroncol29050264. View

Menzin J, Meyers J, Friedman M, Perfect J, Langston A, Danna R . Mortality, length of hospitalization, and costs associated with invasive fungal infections in high-risk patients. Am J Health Syst Pharm. 2009; 66(19):1711-7. DOI: 10.2146/ajhp080325. View

10.

Saito A, Yoshida I, Tanaka S, Sawamura M, Hidaka M, Yoshida S . Efficacy of Intravenous Itraconazole Versus Liposomal Amphotericin B as Empirical Antifungal Therapy in Hematological Malignancy with Persistent Fever and Neutropenia: Study Protocol for a Multicenter, Prospective, Randomized Non-inferiority Trial. Kurume Med J. 2021; 66(4):239-246. DOI: 10.2739/kurumemedj.MS664001. View

11.

Shirazian S, Manifar S, Nodehi R, Shabani M . Oropharyngeal Candida Colonization in Patients with Acute Myeloid Leukemia. Front Dent. 2021; 17(6):1-6. PMC: 7882205. DOI: 10.18502/fid.v17i1.3966. View

12.

Hsu L, Lee D, Yeh S, Bhurani D, Khanh B, Low C . Epidemiology of invasive fungal diseases among patients with haematological disorders in the Asia-Pacific: a prospective observational study. Clin Microbiol Infect. 2015; 21(6):594.e7-11. DOI: 10.1016/j.cmi.2015.02.019. View

13.

Hamzavi S, Amanati A, Badiee P, Kadivar M, Jafarian H, Ghasemi F . Changing face of Candida colonization pattern in pediatric patients with hematological malignancy during repeated hospitalizations, results of a prospective observational study (2016-2017) in shiraz, Iran. BMC Infect Dis. 2019; 19(1):759. PMC: 6717378. DOI: 10.1186/s12879-019-4372-x. View

14.

Lamoth F, Lockhart S, Berkow E, Calandra T . Changes in the epidemiological landscape of invasive candidiasis. J Antimicrob Chemother. 2018; 73(suppl_1):i4-i13. DOI: 10.1093/jac/dkx444. View

15.

Krcmery Jr V, Babela R . Mortality associated with breakthrough candidemia among patients with and those without cancer. Clin Infect Dis. 2002; 35(7):898; author reply 899. DOI: 10.1086/341987. View

16.

Donnelly J, Chen S, Kauffman C, Steinbach W, Baddley J, Verweij P . Revision and Update of the Consensus Definitions of Invasive Fungal Disease From the European Organization for Research and Treatment of Cancer and the Mycoses Study Group Education and Research Consortium. Clin Infect Dis. 2019; 71(6):1367-1376. PMC: 7486838. DOI: 10.1093/cid/ciz1008. View

17.

Alves J, Palma P, Azevedo D, Rello J . Candidemia in the patient with malignancy. Hosp Pract (1995). 2018; 46(5):246-252. DOI: 10.1080/21548331.2018.1508290. View

18.

Valentine J, Morrissey C, Tacey M, Liew D, Patil S, Peleg A . A population-based analysis of invasive fungal disease in haematology-oncology patients using data linkage of state-wide registries and administrative databases: 2005 - 2016. BMC Infect Dis. 2019; 19(1):274. PMC: 6429824. DOI: 10.1186/s12879-019-3901-y. View

19.

Li Y, Yu L . [Current Status and Future Perspectives of Primary Antifungal Prophylaxis in Patients with Hematological Malignancies-Review]. Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2017; 25(2):627-632. DOI: 10.7534/j.issn.1009-2137.2017.02.059. View

20.

Hesstvedt L, Gaustad P, Muller F, Andersen C, Brunborg C, Mylvaganam H . The impact of age on risk assessment, therapeutic practice and outcome in candidemia. Infect Dis (Lond). 2019; 51(6):425-434. DOI: 10.1080/23744235.2019.1595709. View